KOL Insight

Datamonitor Healthcare Non-Alcoholic Steatohepatitis (NASH) KOL Interview – US

This interview with a US key opinion leader (KOL) provides insight into pipeline therapies for non-alcoholic steatohepatitis (NASH), as well as pricing strategies, diagnostic tools, and future treatment rates for the different fibrosis stages of NASH. Key pipeline assets highlighted include Ocaliva, elafibranor, cenicriviroc, and firsocostat.

May 20, 2019

Alzheimer’s Disease KOL Interview – US, Northeast

This interview with a US key opinion leader (KOL) provides insight into data from various late-phase Alzheimer’s disease pipeline therapies, as well as a discussion of the design of these trials. Also discussed are treatment trends and current unmet needs.

January 28, 2019

Alzheimer’s Disease KOL Interview – UK

This interview with a UK key opinion leader (KOL) provides an overview of cost-effectiveness criteria that may be required to bring Alzheimer’s disease products successfully to the clinic in the UK. We also discuss current and potential treatment options, as well as unmet needs in Alzheimer’s disease.

January 20, 2019

Alzheimer’s Disease KOL Interview – US, South

This interview with a US key opinion leader (KOL) provides insight into data from various late-phase Alzheimer’s disease pipeline therapies, as well as a discussion of the design of these trials. Also discussed are treatment trends and current unmet needs.

January 28, 2019

Pediatric Epilepsy KOL Interview – US, West

A US expert in pediatric epilepsy provides insight into the approach to treating different forms of epilepsy. The key opinion leader (KOL) dives into the late-phase pipeline for epilepsy, as well as sharing insight into Epidiolex.

February 18, 2019

Epilepsy KOL Interview – US, West

A US key opinion leader (KOL) discusses the epilepsy treatment landscape, including new market entrant Epidiolex, and provides their perspective on late-phase pipeline anti-epileptic drugs such as Fintepla.

February 18, 2019

Datamonitor Healthcare Chronic Heart Failure KOL Interview – US, West Coast

A US KOL provides insight into current and future therapies for chronic heart failure, as well as key unmet needs in this therapeutic area. Key marketed drugs are highlighted, including Corlanor and Entresto. Significant late-phase pipeline drugs are also covered, with a focus on SGLT-2 inhibitors.

Datamonitor Healthcare Chronic Heart Failure KOL Interview – UK

A UK KOL provides insight into marketed and pipeline therapies for chronic heart failure, as well as key unmet needs in this therapeutic area. Key marketed drugs are highlighted, including Corlanor and Entresto. Significant late-phase pipeline drugs are also covered, with a focus on SGLT-2 inhibitors.

Datamonitor Healthcare Chronic Heart Failure KOL Interview – Germany

A German KOL discusses current marketed therapies and SGLT-2 inhibitors for chronic heart failure, as well as key unmet needs in this therapeutic area.

Datamonitor Healthcare Chronic Heart Failure KOL Interview – US, Southwest

A US KOL provides insight into marketed and pipeline therapies for chronic heart failure, as well as key unmet needs in this therapeutic area. Key marketed drugs are highlighted, including Corlanor and Entresto. Significant late-phase pipeline drugs are also covered, with a focus on SGLT-2 inhibitors.

Datamonitor Healthcare Hepatocellular Carcinoma (HCC) KOL Interview – UK

This interview covers hepatocellular carcinoma (HCC) treatment trends in the UK. We discuss current options for first- and second-line treatment, as well as therapies that are currently in Phase III clinical trials.

February 6, 2019

Datamonitor Healthcare Hepatocellular Carcinoma (HCC) KOL Interview – US, South #2

This interview provides a thorough description of hepatocellular carcinoma (HCC) treatment in the US. All targeted therapies available for HCC treatment are discussed, as well as a discussion of Phase III pipeline drugs and the potential impact these therapies would have if they gain approval.

February 6, 2019

Datamonitor Healthcare Hepatocellular Carcinoma (HCC) KOL Interview – US, South #1

This interview covers hepatocellular carcinoma treatment trends in the US. We discuss current treatment options including the recently approved Keytruda and Lenvima. Also disused are Phase III pipeline therapies Imfinzi and Tecentriq for the first-line setting, along with the potential of PD-1/PD-L1 therapies in the adjuvant setting.

February 6, 2019

ECLIPSE Psoriasis Pulse Survey

This 11-question pulse survey of 74 dermatologists practicing throughout the US and Europe asks respondents their thoughts on results from the ECLIPSE study

January 31, 2019

Datamonitor Healthcare HIV KOL Interview – US #2

A US key opinion leader (KOL) provides insights into the HIV treatment market, including a discussion on prescribing trends, key marketed therapies, impact of generic launches, and pipeline therapies.

Datamonitor Healthcare HIV KOL Interview – US #1

A US key opinion leader (KOL) provides insights into the HIV treatment market, including a discussion on prescribing trends, key marketed therapies, impact of generic launches, and pipeline therapies.

Datamonitor Healthcare HIV KOL Interview – UK

A UK key opinion leader (KOL) provides insights into the HIV treatment market, including a discussion on prescribing trends, key marketed therapies, impact of generic launches, and pipeline therapies.

Datamonitor Healthcare HIV KOL Interview – Germany

A German key opinion leader (KOL) provides insights into the HIV treatment market, including a discussion on prescribing trends, key marketed therapies, impact of generic launches, and pipeline therapies.

2018 ASH Pulse Survey

This 9-question pulse survey of 102 hematologic oncologists practicing throughout the United States and Europe.

January 2, 2019

Datamonitor Healthcare Multiple Myeloma KOL Interview – Midwestern, US

This interview covers the current treatment of multiple myeloma in the US, and the main areas of unmet need.

January 18, 2019

Datamonitor Healthcare Multiple Myeloma KOL Interview – UK

This interview covers the current treatment of multiple myeloma in the UK, and the main areas of unmet need.

January 18, 2019

Datamonitor Healthcare HR+/HER2- Breast Cancer KOL Interview – US, West Coast

A US key opinion leader (KOL) provides insight into the current and future treatment dynamics of HR+/HER2- breast cancer, as well as critical unmet needs in the treatment space.

January 8, 2019

Datamonitor Healthcare HR+/HER2- Breast Cancer KOL Interview – US, Midwest

A US key opinion leader (KOL) provides insight into the current and future treatment dynamics of HR+/HER2- breast cancer, as well as critical unmet needs in the treatment space.

January 8, 2019

Datamonitor Healthcare HR+/HER2- Breast Cancer KOL Interview – UK

A UK key opinion leader (KOL) provides insight into the current and future treatment dynamics of HR+/HER2- breast cancer, as well as critical unmet needs in the treatment space.

January 8, 2019

Major Depressive Disorder KOL Interview – UK

A UK key opinion leader (KOL) provides insight into the critical unmet needs in the depression market, along with future trends. Key late-phase pipeline drugs for major depressive disorder and post-partum depression are covered, with particular focus on Johnson & Johnson’s esketamine.

December 19, 2018

Datamonitor Healthcare Major Depressive Disorder KOL Interview – US #2

A US key opinion leader (KOL) discusses the approach to treating major depressive disorder as well as the most pressing unmet needs in the market, and provides insights into key late-phase pipeline drugs for major depressive disorder.

October 2, 2018

Datamonitor Healthcare Major Depressive Disorder KOL Interview – US #1

A US key opinion leader (KOL) discusses key late-phase pipeline and marketed drugs for major depressive disorder and highlights the significance of unique mechanisms of action in the market.

October 2, 2018

Datamonitor Healthcare Ulcerative Colitis KOL Interviews

Datamonitor Healthcare interviewed two ulcerative colitis (UC) experts, one based in Italy and the other in the US, to gauge their views on approved and late-stage pipeline drugs, treatment challenges and unmet needs and the future treatment of UC.

August 18, 2017

Datamonitor Healthcare Systemic Lupus Erythematosus KOL Interviews

Datamonitor Healthcare interviewed two experts on systemic lupus erythematosus (SLE) based in the US to gauge their views on currently available treatment options, pipeline drugs and challenges with clinical trial design in SLE.

August 18, 2017